You have free access to this content

Cancer

Cover image for Cancer

1 May 2003

Volume 97, Issue 9

Pages 2127–2349

  1. Editorial

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    5. Errata
    1. You have free access to this content
      BRCA-related ovarian carcinoma : Another piece of the puzzle? (pages 2127–2129)

      Stephen C. Rubin

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11341

      The author comments on a report in this issue of Cancer by investigators who used clinical response endpoints and chemoresistance testing to confirm the improved survival of women with hereditary ovarian carcinoma compared with women who had sporadic ovarian carcinoma. The possible use of BRCA mutation status to improve patient care, the future of translational research, and the difficulties in proceeding with large-scale prospective trials are among the topics discussed.

      See also pages 2187–95.

    2. You have free access to this content
      Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant (pages 2130–2133)

      Jennifer L. Schwartz, Ellen L. Mozurkewich and Timothy M. Johnson

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11342

      The authors discuss the issues raised in a report by Daryanani et al. in this issue of Cancer regarding pregnancy and hormonal contraception before, during, or after a woman is diagnosed with melanoma. Their objectives were to address the management of these patients and enhance the information provided by the authors.

      See also pages 2248–53.

    3. You have free access to this content
      Sentinel lymph node biopsy: Beyond melanoma and breast carcinoma (pages 2134–2136)

      Kelly M. McMasters

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11343

      In this issue of Cancer, two groups of investigators present their initial experience with sentinel lymph node (SLN) biopsy in the staging of sweat gland carcinomas. The reports suggest that it is possible to identify clinically occult lymph node metastases from sweat gland carcinoma using SLN biopsy similar to the way that surgeons around the world now routinely stage the regional lymph nodes in patients with melanoma and breast carcinoma. These two articles raise the question of when does it make sense to apply SLN biopsy to cases beyond melanoma and breast carcinoma?

      See also pages 2279–84 and 2285–9.

  2. Original Articles

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    5. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Effect of stereotactic core needle biopsy on pathologic measurement of tumor size of T1 invasive breast carcinomas presenting as mammographic masses (pages 2137–2141)

      Melita Charles, Stephen B. Edge, Janet S. Winston, Thelma C. Hurd, Deborah L. Driscoll and Paul C. Stomper

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11336

      • original image

      Stereotactic core needle biopsy (SCNB) did not alter the pathologic measurement of small breast tumors detected as mammographic masses compared with similar cases with an initial surgical biopsy. Except in the circumstance of complete removal of the tumor by SCNB, the pathologic size and stage of the excised tumor after SCNB was not significantly altered.

    2. You have free access to this content
      Conservative management of Paget disease of the breast with radiotherapy : 10- and 15-year results (pages 2142–2149)

      Jennifer K. Marshall, Kent A. Griffith, Bruce G. Haffty, Lawrence J. Solin, Frank A. Vicini, Beryl McCormick, David E. Wazer, Abram Recht and Lori J. Pierce

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11337

      • original image
      • original image
      • original image

      Women with Paget disease of the breast without evidence of a palpable mass or mammographic density who received breast-conserving surgery (BCS) and radiotherapy (RT) had excellent results at 5 years. The combination of BCS and RT has been confirmed as an appropriate alternative to mastectomy, with excellent rates of local control and cause-specific and overall survival demonstrated at 10 and 15 years.

    3. You have free access to this content
      Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma : Evidence from a tertiary care cohort of chemotherapy-eligible patients (pages 2150–2159)

      Angela DeMichele, Mary Putt, Yawei Zhang, John H. Glick and Sandra Norman

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11338

      • original image
      • original image

      The authors found a strong association between increased age and a decline in the use of adjuvant chemotherapy for patients with breast carcinoma. This finding suggests that, despite consensus guidelines and clinical trial data supporting the use of this therapy, physicians remain reluctant to recommend it to all potentially eligible patients, even among patients age ≤ 70 years, for whom efficacy data are most compelling.

    4. You have free access to this content
      A multigene test for the risk of sporadic breast carcinoma (pages 2160–2170)

      David E. Comings, Radhika Gade-Andavolu, Lawrence A. Cone, Donn Muhleman and James P. MacMurray

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11340

      • original image

      Genes that play a role in risk factors for breast carcinoma, such as the age of onset of menarche, might be breast carcinoma risk genes. Using this hypothesis, the authors evaluated the additive effect of six genes (leptin, leptin receptor, catecol-o-methyltransferase, dopamine D2 receptor, estrogen receptor, and androgen receptor) in 67 women with sporadic breast carcinoma and in 145 sex and gender-matched controls. An additive breast carcinoma risk score also was evaluated by receiver operator characteristic plots.

    5. Genitourinary Disease
      You have free access to this content
      Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma (pages 2171–2179)

      William K. Oh, Patrice Tully, Philip W. Kantoff and Meredith M. Regan

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11344

      • original image
      • original image

      In a survey of physicians who care for patients with prostate carcinoma in New England, 87% of respondents had recommended cytotoxic chemotherapy to patients with hormone-refractory prostate carcinoma. The likelihood of recommending chemotherapy varied by specialty, gender, and percentage of patients in the practice with hormone-refractory disease.

    6. You have free access to this content
      Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract : An alternative therapy (pages 2180–2186)

      Miquel Nogué-Aliguer, Joan Carles, Antonio Arrivi, Oscar Juan, Lorenzo Alonso, Albert Font, Begoña Mellado, Pilar Garrido and Alberto Sáenz

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.10990

      • original image

      Gemcitabine and carboplatin achieve a similar result to doublets using cisplatin. This combination has an acceptable toxicity profile and enables patients with impaired renal function and/or poor performance status and elderly patients to be treated.

    7. Gynecologic Oncology
      You have free access to this content
      Improved survival in women with BRCA-associated ovarian carcinoma (pages 2187–2195)

      Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A. Narod and Beth Y. Karlan

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11310

      • original image
      • original image

      Jewish patients with BRCA-associated ovarian carcinoma had improved survival compared with Jewish patients who had sporadic ovarian carcinoma. This improvement in survival was the result of an enhanced response to platinum-based chemotherapy.

      See also pages 2127–9.

    8. You have free access to this content
      Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma (pages 2196–2202)

      John H. Farley, Kimberly W. Hickey, Jay W. Carlson, G. Scott Rose, Edward R. Kost and Terry A. Harrison

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11371

      • original image

      Adenosquamous histology predicts poor outcome for patients with advanced-stage cervical carcinoma but not for patients with early-stage disease.

    9. Head and Neck Disease
      You have free access to this content
      Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma (pages 2203–2211)

      Eric C. Weinman, Patrick C. Roche, Jan L. Kasperbauer, Steve S. Cha, Dan J. Sargent, John Cheville, Linda M. Murphy, Lieping Chen, Peter J. Wettstein, Bobbie Gostout, Soldano Ferrone and Scott E. Strome

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11311

      • original image
      • original image
      • original image
      • original image

      Tumors that maintain expression of human leukocyte antigen (HLA) processing machinery preferentially escape apoptotic cell death through up-regulation of the antiapoptotic protein, Survivin. Therefore, for tonsillar squamous cell carcinomas that maintain the expression of HLA Class I antigen, overexpression of the antiapoptosis gene, Survivin, may provide an alternative explanation for tumor progression.

    10. Hematologic Malignancies
      You have free access to this content
      Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia : Comparison with adult acute myeloid leukemia (pages 2212–2217)

      Srdan Verstovsek, Taghi Manshouri, Franklin O. Smith, Francis J. Giles, Jorge Cortes, Elihu Estey, Hagop Kantarjian, Michael Keating, Sima Jeha and Maher Albitar

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11313

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Significantly elevated telomerase activity has been found in samples from patients with almost all malignant hematologic diseases. In this report, the results suggest that, for pediatric patients with acute myeloid leukemia, bone marrow telomerase activity is a highly significant prognostic factor.

    11. You have free access to this content
      Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia : The M. D. Anderson experience (pages 2218–2224)

      Guillermo Lazo, Hagop Kantarjian, Elihu Estey, Deborah Thomas, Susan O'Brien and Jorge Cortes

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11314

      • original image
      • original image

      The authors present the experience at The M. D. Anderson Cancer Center with the use of arsenic trioxide in patients with acute promyelocytic leukemia who developed recurrent disease after therapy with all-trans retinoic acid.

    12. You have free access to this content
      Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (pages 2225–2228)

      Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Kevin White, Guillermo Garcia-Manero, Alessandra Ferrajoli, Srdan Verstovsek, William Wierda, Steven Kornblau and Jorge Cortes

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11381

      • original image
      • original image

      A total of 261 patients with Philadelphia chromosome (Ph)-positive, chronic-phase chronic myelogenous leukemia (CML) after interferon therapy failure who were treated with imatinib were analyzed based on the prediction of these patients achieving a complete cytogenetic response. Persistence of 100% Ph-positive cells after ≥ 6 months of imatinib therapy was found to be associated with a subsequent complete cytogenetic response rate of only 0–4%. However, any cytogenetic response after 3–12 months of therapy still was associated with high complete cytogenetic response rates of 35–54%. Thus, patients with Ph-positive CML who have not achieved a cytogenetic response after ≥ 6 months of imatinib should consider alternative therapeutic options.

    13. You have free access to this content
      Trends in leukemia incidence and survival in the United States (1973–1998) (pages 2229–2235)

      Yang Xie, Stella M. Davies, Ying Xiang, Leslie L. Robison and Julie A. Ross

      Version of Record online: 18 APR 2003 | DOI: 10.1002/cncr.11316

      • original image
      • original image

      Since 1973, the incidence of leukemia in the United States has been declining. However, incidence rates are modestly but significantly increasing for individuals younger than 20 years old. In contrast to children, there has been little overall improvement in leukemia survival among adults.

    14. You have free access to this content
      Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area : High rate of disease recurrence following local therapy (pages 2236–2241)

      Catharina Wenzel, Wolfgang Fiebiger, Karin Dieckmann, Michael Formanek, Andreas Chott and Markus Raderer

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11317

      Patients with mucosa-associated lymphoid tissue lymphoma of the head and neck area are at a high risk for early dissemination and subsequent distant disease recurrence when only local therapies are applied. Clinical trials with application of systemic treatment are warranted in these patients.

    15. Lung Disease
      You have free access to this content
      Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial (pages 2242–2247)

      Vera Hirsh, Renaud Whittom, Linda Ofiara, Pierre Desjardins, Joseph Ayoub, Danielle Charpentier, David Small, Javier Pintos and Adrian Langleben

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11319

      • original image

      A weekly paclitaxel and gemcitabine regimen, allowing optimal dose delivery, resulted in good efficacy with minimal toxicity. For selected patients, this regimen could be considered as an alternative to platinum treatments.

    16. Melanoma
      You have free access to this content
      Pregnancy and early-stage melanoma (pages 2248–2253)

      Deepu Daryanani, John T. Plukker, Joanne A. De Hullu, Hilde Kuiper, Raoul E. Nap and Harald J. Hoekstra

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11321

      • original image
      • original image

      Pregnancy does not appear to have an adverse affect on the prognosis of patients with clinically localized, invasive melanoma.

      See also pages 2130–3.

    17. Neuro-Oncology
      You have free access to this content
      Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p (pages 2254–2261)

      Naoya Hashimoto, Mamoru Murakami, Yoshinobu Takahashi, Masahito Fujimoto, Johji Inazawa and Katsuyoshi Mineura

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11322

      • original image
      • original image

      Analysis of the correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors revealed that both loss of 1p and loss of 19q independently and significantly predict survival. A high-resolution deletion map, which displayed unusually narrow deletions, revealed a new, 10.11-megabase region of deletion between D1S513 and D1S458 (1p34.3–36.11).

    18. You have free access to this content
      Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas (pages 2262–2266)

      Michael Glantz, Marc Chamberlain, Qin Liu, N. Scott Litofsky and Lawrence D. Recht

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11323

      • original image
      • original image

      Analysis of the correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors revealed that both loss of 1p and loss of 19q independently and significantly predict survival. A high-resolution deletion map, which displayed unusually narrow deletions, revealed a new, 10.11-megabase region of deletion between D1S513 and D1S458 (1p34.3–36.11).

    19. You have free access to this content
      Neurologic complications of bladder carcinoma : A review of 359 cases (pages 2267–2272)

      Thomas S. Anderson, William F. Regine, Richard Kryscio and Roy A. Patchell

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11354

      Bladder carcinoma is reported to account for approximately 2% of all malignant tumors. The tumor usually spreads by both local invasion and hematogenous dissemination. Although involvement of the nervous system is believed to be relatively uncommon, to the authors' knowledge, the frequency of neurologic complications associated with bladder carcinoma is unknown. In the current study, the authors reviewed a large series of patients to determine the nature and frequency of neurologic complications.

    20. Sarcoma
      You have free access to this content
      Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients (pages 2273–2278)

      Helge W. Taubert, Frank Bartel, Matthias Kappler, Katja Schuster, Axel Meye, Christine Lautenschläger, Barbara Thamm-Mücke, Matthias Bache, Hannelore Schmidt, Hans-Jürgen Holzhausen and Peter Würl

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11326

      • original image
      • original image

      In this study, the correlation between the expression of the hMSH2 and hMLH1 proteins and the survival of soft tissue sarcoma (STS) patients was investigated. A multivariate Cox proportional hazards regression model revealed a significant correlation between the reduced expression of the hMSH2 protein and poor survival. Reduced expression of the hMSH2 protein is an independent negative prognostic factor for STS patients.

    21. Skin and Soft Tissue
      You have free access to this content
      Sentinel lymph node analysis in patients with sweat gland carcinoma (pages 2279–2284)

      Ruby Delgado, Dennis Kraus, Daniel G. Coit and Klaus J. Busam

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11327

      • original image
      • original image
      • original image

      In the current study, the authors present six patients who underwent sentinel lymph node biopsy for various histologic types of sweat gland carcinoma. The detection of lymph node tumor deposits in four patients supports the clinical utility of sentinel lymph node biopsy for the staging of patients with these tumors.

      See also pages 2134–6 and 2285–9.

    22. You have free access to this content
      Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma (pages 2285–2289)

      Paul N. Bogner, Douglas R. Fullen, Lori Lowe, Augusto Paulino, J. Sybil Biermann, Vernon K. Sondak and Lyndon D. Su

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11328

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Sweat gland carcinomas are rare malignant tumors of eccrine origin that not uncommonly metastasize to regional lymph nodes and extranodal sites. Sentinel lymph node biopsy detects early subclinical metastases and aids in guiding treatment.

      See also pages 2134–6 and 2279–84.

    23. Discipline

      Medical Oncology
      You have free access to this content
      Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting (pages 2290–2300)

      Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, Cindy Rittenberg, Mary E. Elmer, Carrie Schmidt, Arlene Taylor, Alexandra D. Carides, Judith K. Evans and Kevin J. Horgan

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11320

      • original image
      • original image
      • original image
      • original image

      In this randomized, controlled clinical trial in patients who received high-dose cisplatin chemotherapy, different 5-day regimens of the neurokinin-1 antagonist aprepitant were given in combination with a standard therapy regimen consisting of a serotonin-3 antagonist (ondansetron) plus dexamethasone. The trial determined that aprepitant 125 mg on Day 1 of chemotherapy followed by aprepitant 80 mg once daily on Days 2–5 was the dose with the most favorable benefit:risk ratio.

    24. You have free access to this content
      Hypersensitivity and idiosyncratic reactions to oxaliplatin (pages 2301–2307)

      Rebecca R. Thomas, Mary G. Quinn, Barbara Schuler and Jean L. Grem

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11379

      • original image

      Three patients are described who experienced hypersensitivity or idiosyncratic reactions during or shortly after the ninth or 11th infusion of oxaliplatin. Their clinical features are described. A review of the literature suggests that the reported incidence of these reactions is approximately 0.5%.

    25. Pathology
      You have free access to this content
      Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA (pages 2308–2317)

      Michèle Beau-Faller, Jean-Christophe Weber, Anne Schneider, Eric Guèrin, Bernard Gasser, Xavier Ducrocq, Daniel Jaeck, Jean-Marie Wihlm, Elisabeth Quoix and Marie-Pierre Gaub

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11324

      • original image

      Detection by allelotyping of simultaneous allelic imbalance but at alternative alleles (AA) was demonstrated in paired samples of either lung primary tumor and plasma or primary colorectal carcinomas and synchronous liver metastasis. In both types of cancer, AA were observed frequently in several chromosomes, indicating that independent events occurred. Alternative alleles are original markers of tumor heterogeneity.

    26. Pediatric Oncology
      You have free access to this content
      Clinical and biologic significance of nuclear unrest in Wilms tumor (pages 2318–2326)

      D. Ashley Hill, Torin D. Shear, Tiebin Liu, Catherine A. Billups, Pratima K. Singh and Jeffrey S. Dome

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11325

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The management of patients who have Wilms tumor with nuclear unrest presents a clinical dilemma, because these tumors share morphologic features with both favorable histology and anaplastic Wilms tumor. In this study, the authors showed that Wilms tumor with nuclear unrest more closely resembles favorable histology than anaplastic histology, both clinically and biologically.

    27. Symptom Control and Palliative Care
      You have free access to this content
      Patients' willingness to participate in symptom-related and disease-modifying research : Results of a research screening initiative in a palliative care clinic (pages 2327–2333)

      Roxane Crowley and David Casarett

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11329

      Screening questions offer a potentially valuable way to identify patients who are willing to participate in research. Further study is needed to define the advantages and disadvantages of this method compared with standard recruitment techniques.

    28. You have free access to this content
      Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement : A randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients (pages 2334–2340)

      Avi A. Weinbroum, Benjamin Bender, Jacob Bickels, Alexander Nirkin, Nissim Marouani, Shoshana Chazam, Isaac Meller and Yehuda Kollender

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11330

      • original image
      • original image

      Dextromethorphan (90 mg once daily for 3 days) was administered to patients undergoing surgery for bone malignancy under combined general and epidural anesthesia. This was followed by postoperative patient-controlled epidural analgesia (PCEA) in a random, double-blind manner. The use of dextromethorphan and PCEA afforded better postoperative pain control and reduced PCEA and rescue drug requirements and sedation compared with placebo.

    29. Translational Research
      You have free access to this content
      Role of E-cadherins in development of lymphatic tumor emboli (pages 2341–2347)

      Anita Gupta, Charuhas G. Deshpande and Sunil Badve

      Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11332

      • original image
      • original image
      • original image
      • original image

      The authors demonstrated that the expression of E-cadherin in high-grade ductal carcinomas is correlated with the presence of prominent lymphatic tumor emboli. This finding, taken in conjunction with the knowledge that intralymphatic emboli in lobular carcinoma (which is characteristically E-cadherin-negative) are rare, suggests that these adhesion molecules (E-cadherins) have a role in tumor development and growth within the lymphatics.

  3. Correspondence

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    5. Errata
    1. You have free access to this content
  4. Errata

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    5. Errata
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION